Tweet

Today at #SITC2019 we’re also discussing our preclinical SRF231 program, a high affinity anti-CD47 antibody. SRF231 displays a range of favorable anti-tumor effects. See our poster: https://t.co/t0UirBMfnQ #ImmunoOncology